Annals of Clinical and Translational Neurology (Apr 2024)

Fatigue predicts quality of life after leucine‐rich glioma‐inactivated 1‐antibody encephalitis

  • Sophie N. M. Binks,
  • Michele Veldsman,
  • Adam E. Handel,
  • Saiju Jacob,
  • Paul Maddison,
  • Jan Coebergh,
  • Sophia Michael,
  • Sudarshini Ramanathan,
  • Ava Easton,
  • Mette Scheller Nissen,
  • Maria Isabel Leite,
  • David Okai,
  • Morten Blaabjerg,
  • Masud Husain,
  • Sarosh R. Irani

DOI
https://doi.org/10.1002/acn3.52006
Journal volume & issue
Vol. 11, no. 4
pp. 1053 – 1058

Abstract

Read online

Abstract Patient‐reported quality‐of‐life (QoL) and carer impacts are not reported after leucine‐rich glioma‐inactivated 1‐antibody encephalitis (LGI1‐Ab‐E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five‐item battery explained most variance in QoL. Wide‐ranging impacts post‐LGI1‐Ab‐E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.